A RANDOMIZED, OPEN-LABEL EXTENSION STUDY TO INVESTIGATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF ROZANOLIXIZUMAB IN ADULT PATIENTS WITH GENERALIZED MYASTHENIA GRAVISProtocol #: 19-1929 Location: University of Colorado Hospital |
Neurological Screening of Controls in an Age-Related Macular Degeneration RegistryProtocol #: 19-1925 Location: University of Colorado Hospital |
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING EFFICACY AND SAFETY OF ROZANOLIXIZUMAB IN ADULT PATIENTS WITH GENERALIZED MYASTHENIA GRAVISProtocol #: 19-1597 Location: University of Colorado Hospital |
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 as Adjunctive Therapy in Focal-onset EpilepsyProtocol #: 19-1620 Location: University of Colorado Hospital |
A Double-Blind, Placebo-Controlled 16-Week Study of the Cognitive Effects of the Oral P38 Alpha Kinase Inhibitor Neflamapimod in Dementia with Lewy Bodies (DLB)Protocol #: 19-1599 Locations: Brain Imaging Center (BIC); University of Colorado Hospital |
A Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (HYQVIA/HyQvia) and Immune Globulin Infusion (Human), 10% (GAMMAGARD LIQUID/KIOVIG) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)Protocol #: 19-1455 Location: University of Colorado Hospital |
An investigation of immune biology and Alzheimers Disease-related biomarkers in asymptomatic, late life mild TBIProtocol #: 19-1423 Location: University of Colorado Hospital |
Feasibility of the Multiple Sclerosis Performance Test for assessment of functional performance measures in patients with Multiple SclerosisProtocol #: 19-1192 Location: University of Colorado Hospital |
Comparative Effectiveness Research for Infantile Spasms V: 12Jan2017Protocol #: 16-2408 Location: Childrens Hospital Colorado |
Neurophysiological Correlates V: 31Jan18Protocol #: 16-1480 Location: Childrens Hospital Colorado |
Natural History of Rett Syndrome and Related DisordersProtocol #: 15-2332 Location: Childrens Hospital Colorado |
Gamma band neural stimulation and its effects on resting state networksProtocol #: 19-1251 Locations: Brain Imaging Center (BIC); Department Specific Free Standing Clinic |
A Two-year Prospective Natural History Study Examining the Use of Neuronal Injury Biomarkers in Autoimmune Encephalitis as a Potential Biomarker for Disease Activity and SeverityProtocol #: 19-0889 Locations: Brain Imaging Center (BIC); Childrens Hospital Colorado; Colorado Research Center; University of Colorado Hospital |
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema following Large Hemispheric InfarctionProtocol #: 19-0675 Location: University of Colorado Hospital |
A Multi-center, Prospective, Longitudinal, Digital Assessment Study of Disease Progression in Subjects with Early, Untreated Parkinson Disease (PD)Protocol #: 19-0865 Location: University of Colorado Hospital |
A PHASE Ib, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF SUBCUTANEOUS OCRELIZUMAB ADMINISTRATION IN PATIENTS WITH MULTIPLE SCLEROSISProtocol #: 19-1040 Location: University of Colorado Hospital |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naive Adult Patients With Generalized Myasthenia GravisProtocol #: 19-0772 Location: University of Colorado Hospital |
An Open-label Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients with Generalized Myasthenia GravisProtocol #: 19-0150 Location: University of Colorado Hospital |
A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD˗9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic FailureProtocol #: 19-0520 Location: University of Colorado Hospital |
Instrumentation of Huntington's Disease Motor Function AssessmentProtocol #: 19-0212 Location: University of Colorado Hospital |
A Phase 3, 4-week, Multicenter, Randomized, Double-blind, Placebocontrolled, Parallel-group Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Autonomic FailureProtocol #: 19-0414 Location: University of Colorado Hospital |
A 14-Week, Double-Blind, Randomized, Three-Arm, Parallel Group Study to Assess the Efficacy and Safety of Two Doses of Pridopidine versus Placebo for the Treatment of Levodopa-Induced Dyskinesia in Patients with Parkinson's Disease (gLIDe)Protocol #: 19-0478 Location: University of Colorado Hospital |
A Phase I/II Study of Nivolumab Plus or Minus Ipilimumab in Combination with Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed MeningiomaProtocol #: 19-0423 Location: University of Colorado Hospital |
AMPLATZERTM PFO Occluder Post Approval StudyThis is a single arm, multi-center study to confirm the safety and effectiveness of the AMPLATZERTM PFO Occluder in the post approval setting To demonstrate safety of the AMPLATZERTM PFO Occluder by assessing the 30-day rate of device- or procedure-related serious adverse events including those that led to death and the effective by assessing the rate of recurrent ischemic stroke through 5 years Protocol #: 19-6502 Location: Memorial Hospital Central |
Parkinson's Disease: Safety and Tolerability of 24-Hour Daily Exposure to ABBV-951 by Continuous Subcutaneous InfusionProtocol #: 19-0025 Location: University of Colorado Hospital |
A Natural History Study of CMT1B, CMT2A, CMT4A and CMT4CProtocol #: 18-2537 Location: University of Colorado Hospital |
A MULTICENTER, OPEN-LABEL SAFETY AND EFFICACY STUDY OF ADS-5102 AMANTADINE EXTENDED RELEASE CAPSULES IN PATIENTS WITH MULTIPLE SCLEROSIS AND WALKING IMPAIRMENTProtocol #: 19-0363 Location: University of Colorado Hospital |
GORE? CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients with Patent Foramen Ovale (PFO): the REDUCE Post Approval StudyThis study will assess the safety and effectiveness of GORE? CARDIOFORM Septal Occluder in a post approval setting and evaluate the quality of operator education and training and transferability of trial experience to a post-market setting. Protocol #: 19-6030 Locations: Harmony Campus; Medical Center of the Rockies |
Bedside Resources to Gauge Intravascular Volume Status in Hypovolemic Infants in the Operating RoomProtocol #: 18-2513 Location: Childrens Hospital Colorado |
Investigating cortical networks disruption and rehabilitation after traumatic brain injuryProtocol #: 19-0049 Locations: Colorado Research Center; Department Specific Free Standing Clinic |
Gene Expression of Cerebral AneurysmsIn this study, we will collect tissue and blood from participants during their epilepsy surgery. Protocol #: 19-0182 Location: University of Colorado Hospital |
Investigating the Contribution of Peripheral versus Central Nervous System Immune Dysfunction to Cognitive AgingProtocol #: 18-2607 Location: University of Colorado Hospital |
Association of depth recordings from the temporal cortex with sleep pattern detection and characterization of sleep dysfunction in patients with refractory epilepsy.Protocol #: 18-2806 Location: University of Colorado Hospital |
Identifying relevant seizure biomarkers from RNS? System recorded electrocorticography for the development of optimized seizure detection algorithmsProtocol #: 18-2089 Location: University of Colorado Hospital |
A PHASE 1B, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO DETERMINE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF DNL201 IN SUBJECTS WITH PARKINSON'S DISEASEProtocol #: 18-2423 Location: University of Colorado Hospital |
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults with Generalized Myasthenia GravisProtocol #: 18-2341 Location: University of Colorado Hospital |
Safety and Efficacy Study of Elezanumab (ABT-555) in Relapsing Forms of Multiple SclerosisProtocol #: 18-2451 Location: University of Colorado Hospital |
Safety and Efficacy Study of Elezanumab (ABT-555) in Progressive Forms of Multiple SclerosisProtocol #: 18-2152 Location: University of Colorado Hospital |
Genomic Translation for ALS CareProtocol #: 18-1768 Location: University of Colorado Hospital |
A RANDOMIZED CONTROLLED STUDY TO COMPARE THE SAFETY AND EFFICACY OF IPX203 WITH IMMEDIATE-RELEASE CARBIDOPA-LEVODOPA IN PARKINSON'S DISEASE PATIENTS WITH MOTOR FLUCTUATIONSProtocol #: 18-2047 Location: University of Colorado Hospital |
A Phase III, Long-Term, Randomized, Double-blind, Placebo-controlled Trial of BHV-4157 in Adult Subjects with Spinocerebellar AtaxiaProtocol #: 18-1875 Location: University of Colorado Hospital |
Determining the Effectiveness of early Intensive Versus Escalation approaches for the treatment of Relapsing-Remitting Multiple Sclerosis (DELIVERMS)Protocol #: 18-1633 Location: University of Colorado Hospital |
Clinical Outcome Measures in Friedreich's AtaxiaProtocol #: 18-1641 Location: University of Colorado Hospital |
A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy STELLAR StudyProtocol #: 18-1336 Location: University of Colorado Hospital |
Peripheral Inflammatory Cytokine Levels in Parkinson DiseaseProtocol #: 18-1356 Location: University of Colorado Hospital |
A Phase 2b/3 Prospective, Randomized, Double-Blind, Sham-Controlled Trial of VTS-270 (2-hydroxypropyl-a-cyclodextrin) in Subjects with Neurologic Manifestations of Niemann-Pick Type C1 (NPC1) DiseaseProtocol #: 18-0997 Location: University of Colorado Hospital |
Conversational Speech in the Diagnosis of Neurocognitive DisordersProtocol #: 18-0456 Location: University of Colorado Hospital |
More than a Movement Disorder: Applying Palliative Care to Parkinson?s Disease v: 12/06/2017Protocol #: 16-1400 Locations: Colorado Research Center; Department Specific Free Standing Clinic |
Microburst VNS Therapy Feasibility Study in Patients with Refractory EpilepsyProtocol #: 18-0995 Location: University of Colorado Hospital |
Neurologic Music Therapy for enhancing fine motor control in Parkinson's Disease 16Apr2018Protocol #: 16-2308 Location: University of Colorado Hospital |
COG ANBL1531 - A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)Protocol #: 18-0971 Location: Childrens Hospital Colorado |
Ruptured Aneurysms Treated with Hydrogel CoilsTo determine occlusion rates and safety when hydrogel coils are used in the treatment of ruptured intracranial aneurysms. Protocol #: 18-6052 Location: Memorial Hospital Central |
Multi-center, randomized, double-blinded assessment of Tecfidera? in extending the time to a first attack in radiologically isolated syndrome (RIS) (ARISE)Protocol #: 16-0121 Location: University of Colorado Hospital |
A Randomized, Placebo Surgery Controlled, Double-blinded, Multi-center, Phase 2 Clinical Trial, Evaluating the Efficacy and Safety of VY-AADC02 in Advanced Parkinson's Disease with Motor FluctuationsStudy is double blind and placebo controlled. Protocol #: 18-0829 Location: University of Colorado Hospital |
Automatic measurement of hand movements toward development of an objective assessment of primary motor symptoms in Parkinson?s diseaseProtocol #: 15-1041 Location: University of Colorado Hospital |
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as an Add-On Therapy to Anti-Inflammatory Disease-Modifying TherapiesProtocol #: 18-0482 Location: University of Colorado Hospital |
AMPLATZERTM PFO Occluder Post Approval StudyProtocol #: 17-2334 Location: University of Colorado Hospital |
Diet and Relapses in Pediatric Multiple SclerosisProtocol #: 18-0393 Locations: Childrens Hospital Colorado; University of Colorado Hospital |
Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS)Protocol #: 15-2388 Location: University of Colorado Hospital |
Application of transcranial alternating current stimulation for modulation of sleep and cognitive performance1).Optimize tACS parameters for duration, intensity and frequencies via utilization of EEG data recorded during tACS stimulation. 2)Determine whether recording artifacts introduced by tACS can confidently be removed from EEG signals. 3). Determine effects of tACS delivered with nested frequencies(multi-frequency signal) vs single frequency tACS, with regard to intrinsic EEG signal, for modulation of SWA coherence and power, as recorded in our overnight EEG sleep data. 4). Determine the cumulative effects of tACS delivered in multiple, consecutive nights on underlying EEG signals, sleep architecture, sleep quality and cognitive function among patients with MCI. 5). Determine if tACS is a viable treatment for disturbances of sleep and cognitive performance among patients with MCI. 6). Generate pilot data and manuscripts to support applications for larger randomized placebo-controlled clinical trials. Protocol #: 16-1875 Locations: Colorado Research Center; Department Specific Free Standing Clinic; University of Colorado Hospital |
Multiple-Biopsy of Infiltrative Glioma (M-BIG) StudyProtocol #: 17-2111 Location: Childrens Hospital Colorado |
Perceived palliative care needs of Huntington's disease patientsProtocol #: 18-0216 Location: University of Colorado Hospital |
Clinical Trial Readiness for SCA1 and SCA3Protocol #: 18-0020 Location: University of Colorado Hospital |
A Proof of Concept Study to Investigate the Effect of IPT803 Adjunct Treatment in Patients with Parkinson's DiseaseProtocol #: 18-0113 Locations: Anschutz Health and Wellness; University of Colorado Hospital |
Validation of a performance-based assessment of functional ability related to cognition in Parkinson's diseaseProtocol #: 15-0170 Locations: Colorado Research Center; Department Specific Free Standing Clinic; University of Colorado Hospital |
Determining the Optimal Treatment Strategy for Patients who have Chronic Migraine with Medication OveruseProtocol #: 16-2179 Location: University of Colorado Hospital |
Risk factors in Early Multiple Sclerosis (RisE-MS)among asymptomatic first degree relatives (FDRs), aged 18-30, of multiple sclerosis (MS) patients: 1: Determine the prevalence of brain/spine MRI lesions disseminated in space (DIS), consistent with MS 2: Gather data on potential risk factors or early signs related to MS development, including markers for: genes, immunological function, environmental factors, neuroaxonal damage, Vitamin D levels, lipid metabolism, activity levels, mood abnormalities, and cognitive function. From this, develop a risk factor score, incorporating all relevant potential markers of increased risk of DIS. 3: To use this pilot, cross-sectional study as a base for development of a long-term, longitudinal, multi-center study to determine genetic and environmental risks for pre-symptomatic MS 4: To create and maintain a biobank of specimens for future analysis as other potential biomarkers become available. Protocol #: 17-1884 Location: University of Colorado Hospital |
Long-term, prospective, multinational, parallel-cohort study monitoring safety in patients with MS newly started on fingolimod once daily or treated with another approved disease-modifying therapyProtocol #: 15-0657 Location: University of Colorado Hospital |
A randomized, double blind, placebo-controlled parallel study of tolerability and efficacy of Cannabidiol (CBD) on tremor in Parkinson's diseaseProtocol #: 17-2318 Location: University of Colorado Hospital |
American Registry for Migraine ResearchProtocol #: 17-2165 Locations: Lone Tree Medical Center; UCHealth Internal Medical Clinic - Lowry; University of Colorado Hospital |
Phase 2 Study of Allogeneic Umbilical Cord Blood Infusion for Adults with Ischemic Stroke - CoBIS 2The primary objective of the study is to determine, in a randomized, placebo controlled trial, the efficacy of a single intravenous (IV) infusion of unrelated donor UCB for improving functional outcomes in patients with ischemic stroke. The secondary objectives are as follows: 1.To describe the safety and tolerability of a single IV infusion of unrelated donor UCB in patients with ischemic stroke 2.To evaluate the efficacy of a single IV infusion of unrelated donor UCB for improvement of neurological symptoms following ischemic stroke 3.To evaluate the efficacy of a single IV infusion of unrelated donor UCB for improvement in quality of life and emotional and cognitive status in patients with ischemic stroke Protocol #: 17-2136 Location: University of Colorado Hospital |
A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTIPLE DOSE STUDY OF CK-2127107 IN TWO ASCENDING DOSE COHORTS OF PATIENTS WITH SPINAL MUSCULAR ATROPHY (SMA)Protocol #: 17-1816 Location: University of Colorado Hospital |
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects with Parkinson's DiseaseProtocol #: 17-1532 Location: University of Colorado Hospital |
Protocol I7S-MC-HBEH Effect of LY3154207 on Cognition in Mild-to-Moderate Parkinson's Disease Dementia (PDD) (The PRESENCE Study)Protocol #: 17-1825 Location: University of Colorado Hospital |
Topiramate as a disease altering therapy for Cryptogenic Sensory Peripheral Neuropathy (CSPN)Protocol #: 17-1751 Location: University of Colorado Hospital |
Transcranial electrical stimulation for the treatment of cervical dystoniaProtocol #: 17-1322 Locations: Colorado Research Center; Department Specific Free Standing Clinic |
Calibrating free-living physical activity characteristics across functionally-limited populations using machine-learned accelerometer approachesRegular physical activity is known to have positive effects on many health outcomes. In research, physical activity is often measured using activity monitors worn on the hip, wrist or ankle. These instruments determine how much physical activity a person does based on the amount of movement the person does. This is done with equations that use the data collected by the activity monitors. However, these equations are usually developed using measurements on healthy people. People who have movement disorders related to diseases such as Parkinson?s and Multiple Sclerosis, or conditions such as knee replacement, stroke, or arthritis have very different movement patterns than people without these diseases. Thus, the equations used to convert activity monitor data will not work well in people with these diseases or conditions. The purpose of this study is to develop equations to measure physical activity using activity monitors in people with movement limitations. Rather than creating specific equations for each individual disease and condition, we will perform simple tests to measure upper and lower body function, and then group people into different clusters based on these tests. Our preliminary studies show that these equations are more accurate than equations based on specific diseases or conditions. Protocol #: 16-2706 Locations: CTRC-adult; University of Colorado Hospital |
The modified Atkins diet in patients with drug resistant epilepsy and the responsive neurostimulator 09Aug2017Protocol #: 17-0888 Location: University of Colorado Hospital |
BEnefits of Stroke Treatment Delivered Using a Mobile Stroke Unit Compared to Standard Management by Emergency Medical Services: The BEST-MSU StudyProtocol #: 15-2114 Locations: Memorial Hospital Central; University of Colorado Hospital |
Phase III: UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY)Protocol #: 17-1170 Location: University of Colorado Hospital |
A PHASE 1B/2, MULTI-CENTER, DOUBLE-BLIND (PRINCIPAL INVESTIGATORS AND STUDY SUBJECTS BLINDED, SPONSOR UNBLINDED), PLACEBO-CONTROLLED, RANDOMIZED, SINGLE-ASCENDING DOSE STUDY TO ASSESS THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF DS-1040B IN SUBJECTS WITH ACUTE ISCHEMIC STROKEProtocol #: 17-6183 Location: Memorial Hospital Central |
Using Next Generation Sequencing to Unravel the Pathogenesis of Sporadic Inclusion Body Myositis (IBM) - The International IBM Consortium Genetic StudyProtocol #: 17-1132 Location: University of Colorado Hospital |
Stereotactic Laser Ablation for Temporal Lobe Epilepsy (SLATE) StudyProtocol #: 17-0873 Location: University of Colorado Hospital |
Diagnostic and Rating Tools for BlepharospasmProtocol #: 16-0017 Location: University of Colorado Hospital |
MULTICENTER 1-YEAR OBSERVATIONAL STUDY OF PATIENTS WHO ARE INITIATING BRIVARACETAMProtocol #: 17-0679 Location: University of Colorado Hospital |
Dystonia Coalition Project 1: Natural History and Biospecimen Repository for DystoniaProtocol #: 11-0647 Location: University of Colorado Hospital |
10-1311 DoneSave Functional connectivity of the motor network in two major subtypes of Parkinson Disease December 24,2015Protocol #: 10-1311 Location: University of Colorado Hospital |
Deep Brain Stimulation (DBS) of the Rostral Zona Incerta (rZI) for Parkinson's Disease (PD): Stereotactic Targeting and Clinical EfficacyProtocol #: 16-1443 Location: University of Colorado Hospital |
Effect of MD1003 in progressive multiple sclerosis: a randomized double blind placebo controlled studyTo demonstrate the superiority of MD1003, 300 mg/day, over placebo to clinically improve patients with progressive multiple sclerosis (MS). Protocol #: 16-1727 Location: University of Colorado Hospital |
Rocky Mountain Multiple Sclerosis Center (RMMSC) Biorepository for the Study of Neuroimmunological DisordersProtocol #: 12-0968 Location: University of Colorado Hospital |
A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary progressive multiple sclerosis followed by extended treatment with open-label BAF312To demonstrate the efficacy of BAF312 relative to placebo in delaying the time to 3-month confirmed disability progression in patients with SPMS as measured by EDSS. Protocol #: 13-2286 Location: University of Colorado Hospital |
A Phase 3, Open-Label Study of the Safety, Efficacy, and Tolerability of Apomorphine Administered by Continuous Subcutaneous Infusion in Advanced Parkinson's Disease Patients with Unsatisfactory Control on Available Therapy.To assess the long-term safety of apomorphine continuous infusion in advanced Parkinson?s disease (PD) patients who are unable to achieve adequate motor control despite optimal treatment with noninvasive therapy. Protocol #: 15-1274 Location: University of Colorado Hospital |
Rocky Mountain Alzheimer's Disease Center at the University of Colorado School of Medicine (RMADC at UCSOM) Longitudinal Biomarker and Clinical Phenotyping StudyTo create a repository of data and samples to be used to answer future research questions Protocol #: 15-1774 Location: University of Colorado Hospital |
A Phase IV Trial of Neuroprotection with ACTH in Acute Optic NeuritisProtocol #: 13-0388 Location: University of Colorado Hospital |
Wireless electroencephalography for continuous monitoring in the EEG LTM unit 12Apr20181. To evaluate the device?s ability to record wireless EEG from patients in the long-term EEG monitoring unit 2. To compare wireless EEG in these recordings to standard-of-care wired EEG Protocol #: 15-0449 Location: University of Colorado Hospital |
NAtalizumab for Prevention of Post-partum Relapses in patients with Multiple Sclerosis 09May2016To assess the efficacy of IV administered natalizumab, monthly for 1 year, in preventing relapses during the postpartum period. Protocol #: 16-0156 Location: University of Colorado Hospital |
A Double-Masked, Placebo-controlled Study with Open-label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects with Neuromyelitis Optica and Neuromyelitis Optica Spectrum DisordersTo compare the efficacy of MEDI-551 versus placebo in reducing the risk of an NMO/NMOSD attack in subjects with NMO/NMOSD. Protocol #: 14-0926 Location: University of Colorado Hospital |
Collaborative International Research in Clinical and Longitudinal Experience for Neuromyelitis Optica (NMO) StudiesTo create a longitudinal collections of samples and data from: 1. Subjects with clinically-defined or highly suspicious for NMO or NMOSD; 2. Affected or unaffected relatives of subjects with clinically defined NMO or NMOSD; 3. Subjects with autoimmune diseases other NMO or NMOSD, such as multiple sclerosis, myasthenia gravis, Graves' disease, lupus, etc. 4. Healthy subjects Protocol #: 13-3181 Location: University of Colorado Hospital |
A Multicenter, Open-Label, Extension Study to Evaluate the Long-term Safety and Efficacy of Patisiran in Patients with Familial Amyloidotic Polyneuropathy Who Have Completed a Prior Clinical Study with PatisiranTo assess the safety and efficacy of long-term dosing with patisiran in transthyretin-mediated amyloidosis (ATTR) patients with familial amyloidotic polyneuropathy (FAP). Protocol #: 15-1259 Location: University of Colorado Hospital |